Skip to main content
. Author manuscript; available in PMC: 2017 Aug 24.
Published in final edited form as: J Neurochem. 2016 Oct 14;139(5):872–885. doi: 10.1111/jnc.13841

Fig. 7.

Fig. 7

Expression of SMases is reduced by QD-siRNA treatment. (a) Acid sphingomyelinase (ASMase) activity in cells that were transfected with siRNA using a commercial lipofection kit. Column 1 and 2 using 20 and 60 picomoles siRNA to knock down Smpd1 in mouse fibroblasts, and column 3 showing enzyme activity from Smpd1 (ASMase) knock out mouse fibroblasts. (b) Left Panel: RT-PCR electrophoresis showing levels of mRNA in cells treated by lipofectin transfected siRNA. Baseline knockdown efficiency varied between 50% and 63.4% by RT-PCR and fluorometric activity assays. Right Panel: Showing relative percentage of control. (c) Sphingomyelinases activity after 24 h treatment with QD-siRNA constructs. Human oligodendroglioma (HOG) cells and HOG cells over-expressing Neutral sphingomyelinase 2 were treated with QD-JB577-siRNA complexes at a molar ratio of 1 QD: 20 JB577: 1 siRNA, and activity was measured by a fluorometric assay. Lipofection was performed with Santa Cruz commercial lipofection kit using 60 picomoles of siRNA. All results were compared to untreated control. (*p = 0.05).